# Apixaban Dose Reduction in Patients With Elevated Drug Levels

Study · id `cardio:ct-nct02809469` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02809469](<https://clinicaltrials.gov/study/NCT02809469>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02809469

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT02809469. Allocation not applicable; no masking; primary purpose prevention. Start 2016-08 (registry gives no type); primary completion 2018-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT02809469, source copy `cardio:ctgov-nct02809469-2016-06-22`, retrieved 2026-10-26)
- Start date: 2016-08 (registry gives no type) (ClinicalTrials.gov record NCT02809469, source copy `cardio:ctgov-nct02809469-2016-06-22`, retrieved 2026-10-26)
- Primary completion: 2018-08 (anticipated) (ClinicalTrials.gov record NCT02809469, source copy `cardio:ctgov-nct02809469-2016-06-22`, retrieved 2026-10-26)
- Completion: 2018-08 (anticipated) (ClinicalTrials.gov record NCT02809469, source copy `cardio:ctgov-nct02809469-2016-06-22`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT02809469, source copy `cardio:ctgov-nct02809469-2016-06-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02809469-2016-06-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Apixaban Dose Reduction in Patients With Elevated Drug Levels
- Acronym: ADREL
- Condition: Atrial Fibrillation
- Intervention (Drug): apixaban dose reduction
- Lead sponsor: Hamilton Health Sciences Corporation
- Lead sponsor class: OTHER
- Collaborator: Population Health Research Institute
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Hamilton Health Sciences Corporation (`cardio:org-hamilton-health-sciences-corporation`)
- Registry lists this organization as a collaborator: Population Health Research Institute (`cardio:org-population-health-research-institute`)

## Provenance

Content hash: adf583f6ebe8a51cff64a895b8ccd360396ccd89f08347b4897d4fce7146a754
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
